LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 174

Search options

  1. Article ; Online: What is Surveillance teaching us (and what it is not?).

    Buch, Maya H

    Seminars in arthritis and rheumatism

    2023  Volume 64S, Page(s) 152334

    MeSH term(s) Humans ; Arthritis, Rheumatoid/drug therapy ; Antirheumatic Agents/therapeutic use ; Pyrroles/therapeutic use
    Chemical Substances Antirheumatic Agents ; Pyrroles
    Language English
    Publishing date 2023-12-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 120247-9
    ISSN 1532-866X ; 0049-0172
    ISSN (online) 1532-866X
    ISSN 0049-0172
    DOI 10.1016/j.semarthrit.2023.152334
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 790: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: 'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps.

    Tan, Yvonne / Buch, Maya H

    RMD open

    2022  Volume 8, Issue 2

    Abstract: The European Alliance of Associations for Rheumatology recently defined difficult to treat (D2T) rheumatoid arthritis (RA) and provided points to consider in its management. This review summarises the key concepts of D2T-RA that underpinned this recent ... ...

    Abstract The European Alliance of Associations for Rheumatology recently defined difficult to treat (D2T) rheumatoid arthritis (RA) and provided points to consider in its management. This review summarises the key concepts of D2T-RA that underpinned this recent guidance. D2T-RA is primarily characterised by failure of at least two different mechanism of action biologic/targeted synthetic disease-modifying antirheumatic drug (DMARDs) with evidence of active/progressive disease. The basis for progressive disease, however, is not limited to clear inflammatory joint pathology, capturing wider contributors to treatment cycling such as comorbidity, obesity and fibromyalgia. This means D2T-RA comprises a heterogeneous population, with a proportion within this exhibiting bona fide treatment-refractory disease. The management points to consider, however, emphasise the importance of checking for the presence of inflammatory pathology before further treatment change. This review suggests additional considerations in the definition of D2T-RA, the potential value in identifying D2T traits and intervening before the development of D2T-RA state and the need for real world evidence of targeted synthetic DMARD in this population to compare to recent trial data. Finally, the review asks whether the presence of D2T-RA implies a failure to treat effectively from the outset, and the need for pharmacological and non-pharmacological management approaches to address the wider D2T-RA population effectively.
    MeSH term(s) Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/epidemiology ; Biological Products/therapeutic use ; Comorbidity ; Humans ; Rheumatology
    Chemical Substances Antirheumatic Agents ; Biological Products
    Language English
    Publishing date 2022-07-23
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2812592-7
    ISSN 2056-5933 ; 2056-5933
    ISSN (online) 2056-5933
    ISSN 2056-5933
    DOI 10.1136/rmdopen-2022-002387
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Response to 'Correspondence to viewpoint 'Defining refractory rheumatoid arthritis' by Buch' by Roodenrijs

    Buch, Maya H

    Annals of the rheumatic diseases

    2018  Volume 78, Issue 10, Page(s) e106

    MeSH term(s) Antirheumatic Agents ; Arthritis, Rheumatoid ; Humans
    Chemical Substances Antirheumatic Agents
    Language English
    Publishing date 2018-08-17
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/annrheumdis-2018-214153
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.114: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 167: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Response to: 'Correspondence on 'Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naive, early rheumatoid arthritis'' by Georgiadis

    Plein, Sven / Buch, Maya H

    Annals of the rheumatic diseases

    2021  Volume 82, Issue 4, Page(s) e90

    MeSH term(s) Humans ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Etanercept/therapeutic use ; Treatment Outcome ; Drug Therapy, Combination ; Biological Products/therapeutic use
    Chemical Substances Antirheumatic Agents ; Etanercept (OP401G7OJC) ; Biological Products
    Language English
    Publishing date 2021-02-08
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/annrheumdis-2021-219926
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.114: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 167: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Managing the selection of placebo group switched to experimental treatment group in post-randomised controlled trial extension studies.

    Buch, Maya H / Maksymowych, Walter P / Boers, Maarten

    Annals of the rheumatic diseases

    2022  Volume 81, Issue 5, Page(s) 741–742

    MeSH term(s) Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Humans ; Randomized Controlled Trials as Topic
    Chemical Substances Antirheumatic Agents
    Language English
    Publishing date 2022-01-13
    Publishing country England
    Document type Journal Article
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/annrheumdis-2021-221775
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.114: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 167: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Defining refractory rheumatoid arthritis.

    Buch, Maya H

    Annals of the rheumatic diseases

    2018  Volume 77, Issue 7, Page(s) 966–969

    Abstract: While biologic disease-modifying antirheumatic drugs (bDMARDs) have transformed outcomes of people with rheumatoid arthritis (RA), a proportion of patients are refractory to multiple bDMARDs. Definitions of refractory RA thus far have been arbitrary, and ...

    Abstract While biologic disease-modifying antirheumatic drugs (bDMARDs) have transformed outcomes of people with rheumatoid arthritis (RA), a proportion of patients are refractory to multiple bDMARDs. Definitions of refractory RA thus far have been arbitrary, and outcome data and impact of such cohorts remain limited. Extrapolation from randomised controlled trial and some real-life data suggest approximately 20% progress onto a third bDMARD with a more modest proportion failing additional bDMARDs. This viewpoint discusses an opinion of refractory RA disease and proposes key principles to accurately identify refractory cohorts. These include demonstrating presence of persistent inflammation despite multiple therapies and acknowledging development of antidrug antibody. Potential basis of refractory disease is summarised, and suggestions for an initial approach in the future evaluation of refractory disease are offered. Specific investigation of refractory RA disease is necessary to inform the clinical need and provide a basis for robust investigation of underlying mechanisms.
    MeSH term(s) Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/classification ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/physiopathology ; Biological Products/therapeutic use ; Drug Resistance, Multiple ; Female ; Humans ; Male ; Needs Assessment ; Pain, Intractable/classification ; Pain, Intractable/drug therapy ; Pain, Intractable/physiopathology ; Prognosis ; Recurrence ; Severity of Illness Index ; Treatment Failure ; Treatment Outcome
    Chemical Substances Antirheumatic Agents ; Biological Products
    Language English
    Publishing date 2018-03-27
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/annrheumdis-2017-212862
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.114: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 167: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Efficacy of tumour-necrosis factor-inhibitor in moderate disease activity rheumatoid arthritis: sub-analysis of the 'VEDERA' trial.

    Shukla, Rudresh / Emery, Paul / Buch, Maya H

    Rheumatology (Oxford, England)

    2021  Volume 61, Issue 2, Page(s) 868–869

    MeSH term(s) Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Etanercept/therapeutic use ; Female ; Humans ; Male ; Middle Aged ; Patient Acuity ; Treatment Outcome ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
    Chemical Substances Antirheumatic Agents ; Tumor Necrosis Factor-alpha ; Etanercept (OP401G7OJC)
    Language English
    Publishing date 2021-10-19
    Publishing country England
    Document type Letter ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/keab766
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 240: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 497: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Use of coronarycomputed tomography for cardiovascular risk assessment in immune-mediated inflammatory diseases.

    Peverelli, Marta / Maughan, Robert T / Gopalan, Deepa / Dweck, Marc R / Dey, Damini / Buch, Maya H / Rudd, James H F / Tarkin, Jason M

    Heart (British Cardiac Society)

    2024  Volume 110, Issue 8, Page(s) 545–551

    Abstract: Immune-mediated inflammatory diseases (IMIDs) are recognised risk factors for accelerated atherosclerotic cardiovascular disease (CVD), particularly in younger individuals and women who lack traditional CVD risk factors. Reflective of the critical role ... ...

    Abstract Immune-mediated inflammatory diseases (IMIDs) are recognised risk factors for accelerated atherosclerotic cardiovascular disease (CVD), particularly in younger individuals and women who lack traditional CVD risk factors. Reflective of the critical role that inflammation plays in the formation, progression and rupture of atherosclerotic plaques, research into immune mechanisms of CVD has led to the identification of a range of therapeutic targets that are the subject of ongoing clinical trials. Several key inflammatory pathways implicated in the pathogenesis of atherosclerosis are targeted in people with IMIDs. However, cardiovascular risk continues to be systematically underestimated by conventional risk assessment tools in the IMID population, resulting in considerable excess CVD burden and mortality. Hence, there is a pressing need to improve methods for CVD risk-stratification among patients with IMIDs, to better guide the use of statins and other prognostic interventions. CT coronary angiography (CTCA) is the current first-line investigation for diagnosing and assessing the severity of coronary atherosclerosis in many individuals with suspected angina. Whether CTCA is also useful in the general population for reclassifying asymptomatic individuals and improving long-term prognosis remains unknown. However, in the context of IMIDs, it is conceivable that the information provided by CTCA, including state-of-the-art assessments of coronary plaque, could be an important clinical adjunct in this high-risk patient population. This narrative review discusses the current literature about the use of coronary CT for CVD risk-stratification in three of the most common IMIDs including rheumatoid arthritis, psoriasis and systemic lupus erythematosus.
    MeSH term(s) Humans ; Female ; Cardiovascular Diseases/diagnostic imaging ; Cardiovascular Diseases/epidemiology ; Risk Factors ; Coronary Artery Disease/diagnostic imaging ; Coronary Artery Disease/complications ; Tomography, X-Ray Computed ; Atherosclerosis ; Risk Assessment ; Plaque, Atherosclerotic/complications ; Coronary Angiography/adverse effects ; Heart Disease Risk Factors ; Immunomodulating Agents
    Chemical Substances Immunomodulating Agents
    Language English
    Publishing date 2024-03-22
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1303417-0
    ISSN 1468-201X ; 1355-6037
    ISSN (online) 1468-201X
    ISSN 1355-6037
    DOI 10.1136/heartjnl-2022-321403
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui IV Zs.40: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 112: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician.

    Szekanecz, Zoltán / Buch, Maya H / Charles-Schoeman, Christina / Galloway, James / Karpouzas, George A / Kristensen, Lars Erik / Ytterberg, Steven R / Hamar, Attila / Fleischmann, Roy

    Nature reviews. Rheumatology

    2024  Volume 20, Issue 3, Page(s) 196

    Language English
    Publishing date 2024-02-01
    Publishing country United States
    Document type Published Erratum
    ZDB-ID 2491532-4
    ISSN 1759-4804 ; 1759-4790
    ISSN (online) 1759-4804
    ISSN 1759-4790
    DOI 10.1038/s41584-024-01085-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6338: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Transforming clinical trials in rheumatology: towards patient-centric precision medicine.

    Pitzalis, Costantino / Choy, Ernest H S / Buch, Maya H

    Nature reviews. Rheumatology

    2020  Volume 16, Issue 10, Page(s) 590–599

    Abstract: Despite the success of targeted therapies in the treatment of inflammatory arthritides, the lack of predictive biomarkers drives a 'trial and error' approach to treatment allocation, leading to variable and/or unsatisfactory responses. In-depth ... ...

    Abstract Despite the success of targeted therapies in the treatment of inflammatory arthritides, the lack of predictive biomarkers drives a 'trial and error' approach to treatment allocation, leading to variable and/or unsatisfactory responses. In-depth characterization of the synovial tissue in rheumatoid arthritis, as well as psoriatic arthritis and spondyloarthritis, is bringing new insights into the diverse cellular and molecular features of these diseases and their potential links with different clinical and treatment-response phenotypes. Such progress raises the tantalizing prospect of improving response rates by matching the use of specific agents to the cognate target pathways that might drive particular disease subtypes in specific patient groups. Innovative patient-centric, molecular pathology-driven clinical trial approaches are needed to achieve this goal. Whilst progress is clearly being made, it is important to emphasize that this field is still in its infancy and there are a number of potential barriers to realizing the premise of patient-centric clinical trials.
    MeSH term(s) Antirheumatic Agents/therapeutic use ; Arthritis, Psoriatic/immunology ; Arthritis, Psoriatic/therapy ; Arthritis, Rheumatoid/immunology ; Arthritis, Rheumatoid/therapy ; Biological Factors/therapeutic use ; Biomarkers/analysis ; Humans ; Patient-Centered Care/methods ; Precision Medicine/methods ; Randomized Controlled Trials as Topic ; Rheumatology/trends ; Safety ; Spondylarthritis/immunology ; Spondylarthritis/therapy ; Synovial Fluid/drug effects ; Synovial Fluid/metabolism ; Treatment Outcome
    Chemical Substances Antirheumatic Agents ; Biological Factors ; Biomarkers
    Language English
    Publishing date 2020-09-04
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2491532-4
    ISSN 1759-4804 ; 1759-4790
    ISSN (online) 1759-4804
    ISSN 1759-4790
    DOI 10.1038/s41584-020-0491-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6338: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top